Comparative Pharmacology
Head-to-head clinical analysis: KEFLET versus SUPRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFLET versus SUPRAX.
KEFLET vs SUPRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
400 mg orally once daily or 200 mg orally every 12 hours.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 11-15 hours in severe renal impairment (CrCl <20 mL/min).
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Renal: 50-55% unchanged in urine; biliary/fecal: 10-20% (biliary excretion); remainder metabolized or excreted via feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic